Abstract Number: 2114 • 2018 ACR/ARHP Annual Meeting
Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes
Background/Purpose: Photosensitivity, defined as increased cutaneous erythema and inflammation after ultraviolet light (UV) exposure, is a hallmark of patients with systemic lupus erythematosus (SLE), cutaneous…Abstract Number: 2807 • 2018 ACR/ARHP Annual Meeting
Association of Exposure to Childhood Abuse with Incident Systemic Lupus Erythematosus in a Longitudinal Cohort of Women
Background/Purpose: Prior studies demonstrated associations between post-traumatic stress disorder and increased risk of incident SLE and between childhood trauma and increased risk of hospitalization for…Abstract Number: 461 • 2018 ACR/ARHP Annual Meeting
Ofatumumab Use in Childhood-Onset Systemic Lupus Erythematosus: A Single-Center Experience
Background/Purpose: Ofatumumab is a fully human anti-CD20 monoclonal antibody that has been approved for the treatment of chronic lymphocytic leukemia. It has been increasingly used…Abstract Number: 750 • 2018 ACR/ARHP Annual Meeting
Positive Remodeling Index and Low Attenuation Non-Calcified Coronary Plaques: Markers of Vulnerable Coronary Plaques in Systemic Lupus?
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. Positive remodeling index and presence of low…Abstract Number: 1709 • 2018 ACR/ARHP Annual Meeting
Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference
Background/Purpose: Lupus is an autoimmune disease with multitude of symptoms that are often not fully controlled by standard biomedical treatments. This study was designed to…Abstract Number: 2118 • 2018 ACR/ARHP Annual Meeting
Prevalence of Acquired Activated Protein C Resistance and Anti-Protein C Antibodies in Systemic Lupus Erythematosus
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterised by increased cardiovascular risk, with a 5-20 fold increased risk for venous thromboembolism (VTE)…Abstract Number: 2833 • 2018 ACR/ARHP Annual Meeting
Complement Activation Is a Feature of Diseases in the Lupus Spectrum
Background/Purpose: We showed previously that complement activation - cell-bound complement activation products (CB-CAPS) or multi-analyte assay panel (MAP) - is a sensitive and specific biomarker…Abstract Number: 466 • 2018 ACR/ARHP Annual Meeting
Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Background/Purpose: Streptococcus pneumonia is a leading cause of illness in children worldwide and can lead to death in those with an immunosuppressed status. Given the…Abstract Number: 751 • 2018 ACR/ARHP Annual Meeting
Coronary Plaque Burden in Patients with Lupus Compared to Healthy Volunteers
Background/Purpose: Accelerated atherosclerosis leading to premature coronary artery disease remains the major cause of late death in SLE. We sought to characterize noncalcified and calcified…Abstract Number: 1714 • 2018 ACR/ARHP Annual Meeting
Global Consensus Building and Prioritization of Major Challenges in Lupus Diagnosis, Care, Treatment and Research
Background/Purpose: The Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus initiative seeking to identify and prioritize top barriers in lupus impacting…Abstract Number: 2124 • 2018 ACR/ARHP Annual Meeting
Bacterial Biofilm Product Curli/Edna Induces NETs and Serum Anti-Curli/Edna Levels Correlate with Bacteriuria and Lupus Activity
Background/Purpose: Infections are a major contributor to lupus disease. We have previously demonstrated that bacterial amyloid curli, produced by E.coli, can accelerate disease in mouse…Abstract Number: 2846 • 2018 ACR/ARHP Annual Meeting
Foot and Lower Limb Characteristics in People with SLE: A Comparison with Age- and Sex-Matched Healthy Control Participants
Background/Purpose: People with SLE report joint pain and swelling, impaired circulation, cutaneous lesions and foot deformity. Foot- and lower-limb-related functional impairment has also been described…Abstract Number: 468 • 2018 ACR/ARHP Annual Meeting
Baseline Features and Outcomes of Pediatric-Onset Discoid Lupus Erythematosus: Interim Data Analysis of a Multicenter Retrospective Cohort Study
Background/Purpose: Discoid lupus erythematosus (DLE) is rare in children. Prior studies suggest 25-30% of children with skin-limited DLE are diagnosed with systemic lupus erythematosus (SLE)…Abstract Number: 763 • 2018 ACR/ARHP Annual Meeting
Comparison of Clinical Characteristics and Outcome between Isolated and Classic Lupus Nephritis
Comparison of clinical characteristics and outcome between isolated and classic lupus nephritisBackground/Purpose: Lupus nephritis (LN) is a serious manifestation of systemic lupus erythematosus (SLE). Rarely,…Abstract Number: 1843 • 2018 ACR/ARHP Annual Meeting
Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
Background/Purpose: We previously demonstrated that a small group of high risk, high cost patients (HRHC) account for majority of the hospitalizations, length of stay (LOS)…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 31
- Next Page »